Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities.
暂无分享,去创建一个
Punit Marathe | John S Tokarski | Toomas Mitt | W. Humphreys | J. Tokarski | M. Poss | J. Hunt | F. Lee | N. Pavletich | S. D. Kimball | K. Webster | R. Misra | Hai-yun Xiao | K. Kim | Songfeng Lu | J. Mulheron | R. Batorsky | J. Sack | D. B. Rawlins | Weifang Shan | K. Kellar | I. Bursuker | L. Qian | W. Han | T. Mitt | Z. Cai | Hong Zhu | Chiehying Y Chang | A. Kamath | P. Marathe | U. Roongta | D. Bol | C. Fairchild | John S Sack | Zhen-Wei Cai | Ligang Qian | John T Hunt | Amrita Kamath | Raj N Misra | David B Rawlins | Weifang Shan | Isia Bursuker | Janet G Mulheron | S David Kimball | Kevin R Webster | Michael A Poss | Francis Y Lee | Kyoung Soon Kim | Hai-Yun Xiao | Songfeng Lu | Wen-Ching Han | Hong Zhu | Chieh Ying Chang | Nikola Pavletich | William G Humphreys | Kristen A Kellar | Urvashi Roongta | Roberta Batorsky | David Bol | Craig R Fairchild
[1] C. D. Hurd,et al. The 2-Aminothiazoles , 1949 .
[2] A. Pardee,et al. A restriction point for control of normal animal cell proliferation. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[3] J. Pines,et al. Cyclins, CDKs and cancer. , 1995, Seminars in cancer biology.
[4] J. Nesland,et al. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. , 1998, The American journal of pathology.
[5] F. Lee,et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] L Meijer,et al. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases. , 1998, Bioorganic & medicinal chemistry letters.
[7] T. Fojo,et al. Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.
[8] W. Humphreys,et al. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. , 2000, Journal of medicinal chemistry.
[9] C. Cordon-Cardo,et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. , 1999, Journal of the National Cancer Institute.
[10] E. Sausville,et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. , 1996, International journal of oncology.
[11] R. Tanner,et al. Peptide synthesis by a combination of solid-phase and solution methods. I: A new very acid-labile anchor group for the solid phase synthesis of fully protected fragments , 1988 .
[12] L. Meijer,et al. ATP-site directed inhibitors of cyclin-dependent kinases. , 1999, Current medicinal chemistry.
[13] L Meijer,et al. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. , 2000, Anti-cancer drug design.
[14] L. Kuyper,et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. , 2000, Journal of medicinal chemistry.
[15] E. Sausville,et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. , 1992, Journal of the National Cancer Institute.
[16] A. Haemers,et al. Thiazolopyridine analogs of naldixic acid. 1. Thiazolo[5,4‐b]pyridines , 1984 .
[17] E. Campo,et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. , 1998, The American journal of pathology.
[18] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[19] J. Endicott,et al. Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. , 1999, Pharmacology & therapeutics.
[20] R. Chetty,et al. Cyclin E in human cancers , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[21] Young-Tae Chang,et al. Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors , 2000 .
[22] N. Pavletich. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. , 1999, Journal of molecular biology.
[23] J. Pines,et al. The cell cycle kinases. , 1994, Seminars in cancer biology.
[24] F. Lallemand,et al. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines. , 1997, Anti-cancer drugs.
[25] C. Sherr. Cancer Cell Cycles , 1996, Science.
[26] K. Fukasawa,et al. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. , 2001, Journal of medicinal chemistry.
[27] Herman Yeger,et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer , 1997, Nature Medicine.
[28] K. Webster,et al. The therapeutic potential of targeting the cell cycle. , 1998, Expert opinion on investigational drugs.
[29] P. A. Harris,et al. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. , 2001, Journal of medicinal chemistry.
[30] W. Kaelin,et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[31] S. Coulton,et al. The chemistry of pseudomonic acid , 1987 .
[32] M. Brattain,et al. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. , 1991, Cancer research.
[33] N. F. Osborne,et al. The Chemistry of Pseudomonic Acid.† 18. Heterocyclic Replacement of the α,β-Unsaturated Ester: Synthesis, Molecular Modeling, and Antibacterial Activity1 , 1997 .
[34] T Honma,et al. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. , 2001, Journal of medicinal chemistry.
[35] S. Steinberg,et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] S H Kim,et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.
[37] T. Ibata,et al. Formation and Reaction of Oxazoles. Synthesis of N-Substituted 2-(Aminomethyl)oxazoles , 1989 .
[38] G L Trainor,et al. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. , 2000, Journal of medicinal chemistry.
[39] D. Boschelli,et al. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. , 2000, Journal of medicinal chemistry.
[40] M. Kitagawa,et al. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. , 1993, Oncogene.
[41] D. Carson,et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers , 1994, Nature.
[42] A Joly,et al. CVT-313, a Specific and Potent Inhibitor of CDK2 That Prevents Neointimal Proliferation* , 1997, The Journal of Biological Chemistry.
[43] J. Adams,et al. Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases. , 1999, Current opinion in drug discovery & development.
[44] L. Hartwell,et al. Cell cycle control and cancer. , 1994, Science.
[45] T. Hunter,et al. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age , 1994, Cell.
[46] J. Blow,et al. Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.
[47] Kornelia Polyak,et al. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.
[48] T. Ibata,et al. The BF3 catalyzed decomposition of diazocarbonyl compounds in nitriles: Synthesis of oxazoles. , 1978 .
[49] S. Groshen,et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. , 1998, Journal of the National Cancer Institute.